CVS Caremark Settles FTC Litigation with New Pricing Transparency Rules
CVS Caremark has reached a global settlement with the Federal Trade Commission, ending long-standing litigation over its pharmacy benefit management practices. The agreement forces the company to overhaul its pricing structures, mandate point-of-sale rebates, and implement strict disclosure requirements for drug costs and broker compensation across its network.
The settlement requires the pharmacy giant to shift away from traditional spread pricing and rebate guarantees, moving instead toward a model that aligns member costs with the actual net price of medications. Ed DeVaney, president of CVS Caremark, stated that the company will now standardize point-of-sale rebate passthroughs to ensure drug cost savings reach patients directly at the pharmacy counter. This policy shift aims to address federal concerns regarding vertical integration and transparency within the pharmacy benefits sector.
Under the new terms, CVS Caremark will cap insulin costs at $25 per month for members and begin delinking manufacturer compensation from list prices. The company is also transitioning to acquisition-based reimbursement for independent retail pharmacies to better reflect actual drug costs. These measures are designed to provide greater predictability for the 88 million plan members currently managed by the firm, while expanding reporting requirements for consultants and brokers. The company plans to implement these changes according to a timeline established with federal regulators to ensure compliance across its nationwide network of 9,000 retail locations.
Comments (0)
No comments yet. Be the first!